ReAlta Life Sciences Doses First Patient in Phase 2 Trial
NORFOLK, Va. — ReAlta Life Sciences, Inc. ("ReAlta" or the "Company") has achieved a key milestone by announcing that the first patient has been administered RLS-0071 in its Phase 2 clinical trial. This investigational drug is aimed at hospitalized patients dealing with moderate to severe steroid-refractory acute graft-versus-host disease (aGvHD), a serious and often life-threatening complication that can arise following hematopoietic stem cell transplantation.
The Significance of Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation is one of the most transformative treatments available for those battling cancer, autoimmune diseases, sickle cell disease, and other severe health issues. Yet, complications such as acute graft-versus-host disease can create substantial risks, leading to severe inflammation and damage as the donor's immune cells attack the recipient's body. Dr. Kenji Cunnion, Chief Medical Officer at ReAlta, expresses optimism about RLS-0071, emphasizing its potential to enhance patient outcomes in the face of this complex challenge.
Understanding Steroid-Refractory aGvHD
For patients who suffer from aGvHD and don’t respond sufficiently to standard steroid treatments, the available options are quite limited. This shortage of effective treatments results in escalating inflammation, significant organ damage, and a higher risk of mortality. In the U.S., EU, and Japan, it’s estimated that around 4,000 patients a year develop steroid-refractory aGvHD, highlighting the urgent need for innovative therapies like RLS-0071.
Introducing RLS-0071
RLS-0071 offers a fresh approach to treatment, derived from ReAlta's pioneering EPICC peptide platform. This investigational medication aims to bridge existing gaps in therapy by using a dual-targeting mechanism that modulates both complement and innate inflammatory pathways. Recently, RLS-0071 achieved Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA), underscoring its potential to meet critical medical needs.
RLS-0071 in Clinical Trials
In addition to its focus on aGvHD, ReAlta is also conducting Phase 2 trials of RLS-0071 for newborns diagnosed with hypoxic ischemic encephalopathy (HIE) and for patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AE-COPD). These studies are crucial as they investigate RLS-0071's full therapeutic potential across different patient groups.
About the Ongoing Phase 2 Study
The Phase 2 clinical trial is an open-label, prospective, dose-escalation study designed to assess the safety, tolerability, and efficacy of RLS-0071 in treating steroid-refractory aGvHD in hospitalized patients. The main goals of the study include evaluating safety and the overall response rate among participants receiving RLS-0071 alone or in combination with standard therapies.
ReAlta Life Sciences Overview
Founded in 2018 and based in Norfolk, Virginia, ReAlta Life Sciences, Inc. is committed to saving lives through innovative biopharmaceutical solutions aimed at rare and acute inflammatory diseases. Central to their therapeutic strategy is the EPICC peptide platform, which draws on unique properties derived from the human astrovirus. This platform seeks to inhibit harmful inflammatory responses and prevent the tissue damage that can arise from overstimulated immune reactions. The company’s mission has led to multiple designations from regulatory agencies, emphasizing its commitment to addressing serious conditions like HIE, aGvHD, and AE-COPD.
For additional information on their ongoing studies and updates, visit ReAlta Life Sciences.
Frequently Asked Questions
What is RLS-0071?
RLS-0071 is an investigational treatment developed by ReAlta Life Sciences for steroid-refractory acute graft-versus-host disease (aGvHD).
Why is RLS-0071 significant?
This treatment features a unique dual mechanism of action that targets inflammatory pathways, potentially offering new hope to patients dealing with severe post-transplant complications.
How many patients develop steroid-refractory aGvHD annually?
Each year, around 4,000 patients in the U.S., EU, and Japan develop steroid-refractory aGvHD, signaling a pressing need for effective treatment solutions.
What designations has RLS-0071 received?
RLS-0071 has been awarded Orphan Drug Designation and Fast Track Designation by the U.S. FDA, which enhances its path to development and improves access for patients.
When did ReAlta Life Sciences begin its operations?
ReAlta Life Sciences was founded in 2018, with a mission to innovate treatments for serious inflammatory diseases.
